Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy research hub

A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy

This clinical study tests whether a new medicine called depemokimab works as well as an existing treatment, mepolizumab, for adults with a rare blood vessel condition called EGPA. The 52-week trial looks at whether depemokimab can keep symptoms under control while helping patients safely reduce their daily steroid tablets.